There remains an important need to better understand and predict the renal effects of HBOCs in recipients that may be affected by pre-existing conditions including advanced age, diabetes, infection, ischemia, and chronic disease that render kidneys more susceptible to Hb or heme toxicity (26, 48–50). The gene discussed is GSTM1; the disease is ischemia.